FDA AI Guidance 2026: Drug Manufacturing & Digital Health Analyze the FDA CDER 2026 guidance pipeline for artificial intelligence in drug manufacturing and digital health technologies in pharmaceutical development
Psychiatry 182, 516524
Baseline Assessment IGF-1 serum levels Fasting glucose and HbA1c Comprehensive Metabolic Panel Cancer screening when appropriate Complete Blood Count Follow-Up Monitoring Monthly fasting glucose IGF-1 levels at 46 weeks Clinical assessment during follow-up visits Metabolic monitoring every three months Clinical Evidence Summary Several published studies support the potential applications of IGF-1 LR3 in muscle development, tissue repair, and metabolic optimization
[DOI] [PMC free article] [PubMed] [Google Scholar] Pu J, Fang FF, Li XQ, Shu ZH, Jiang YP, Han T, Peng W, Zheng CJ
Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.